Literature DB >> 24433859

Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Peter S Dragovich1, Guiling Zhao2, Timm Baumeister3, Brandon Bravo2, Anthony M Giannetti2, Yen-Ching Ho3, Rongbao Hua4, Guangkun Li4, Xiaorong Liang2, Xiaolei Ma2, Thomas O'Brien2, Angela Oh2, Nicholas J Skelton2, Chengcheng Wang5, Weiru Wang2, Yunli Wang4, Yang Xiao2, Po-wai Yuen4, Mark Zak2, Qiang Zhao5, Xiaozhang Zheng3.   

Abstract

The fragment-based identification of two novel and potent biochemical inhibitors of the nicotinamide phosphoribosyltransferase (NAMPT) enzyme is described. These compounds (51 and 63) incorporate an amide moiety derived from 3-aminopyridine, and are thus structurally distinct from other known anti-NAMPT agents. Each exhibits potent inhibition of NAMPT biochemical activity (IC50=19 and 15 nM, respectively) as well as robust antiproliferative properties in A2780 cell culture experiments (IC50=121 and 99 nM, respectively). However, additional biological studies indicate that only inhibitor 51 exerts its A2780 cell culture effects via a NAMPT-mediated mechanism. The crystal structures of both 51 and 63 in complex with NAMPT are also independently described.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fragment-based design; NAMPT; Nicotinamide phosphoribosyltransferase; Structure-based design; Surface plasmon resonance; X-ray crystal structure

Mesh:

Substances:

Year:  2013        PMID: 24433859     DOI: 10.1016/j.bmcl.2013.12.062

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.

Authors:  Erin M Kropp; Bryndon J Oleson; Katarzyna A Broniowska; Subarna Bhattacharya; Alexandra C Chadwick; Anne R Diers; Qinghui Hu; Daisy Sahoo; Neil Hogg; Kenneth R Boheler; John A Corbett; Rebekah L Gundry
Journal:  Stem Cells Transl Med       Date:  2015-04-01       Impact factor: 6.940

2.  Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.

Authors:  Kayvan R Keshari; David M Wilson; Mark Van Criekinge; Renuka Sriram; Bertram L Koelsch; Zhen J Wang; Henry F VanBrocklin; Donna M Peehl; Tom O'Brien; Deepak Sampath; Richard A D Carano; John Kurhanewicz
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

3.  Cardiomyocyte Differentiation Promotes Cell Survival During Nicotinamide Phosphoribosyltransferase Inhibition Through Increased Maintenance of Cellular Energy Stores.

Authors:  Erin M Kropp; Katarzyna A Broniowska; Matthew Waas; Alyssa Nycz; John A Corbett; Rebekah L Gundry
Journal:  Stem Cells Transl Med       Date:  2017-02-22       Impact factor: 6.940

4.  Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening.

Authors:  Daisuke Yamaguchi; Takamichi Imaizumi; Kaori Yagi; Yuichi Matsumoto; Takayuki Nakashima; Akiyo Hirose; Naomi Kashima; Yukino Nosaka; Tomoko Hamada; Katsuya Okawa; Yoichi Nishiya; Kazuo Kubo
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

Review 5.  From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.

Authors:  Yumeng Zhu; Ping Xu; Xuan Huang; Wen Shuai; Li Liu; Shuai Zhang; Rui Zhao; Xiuying Hu; Guan Wang
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

6.  Small Molecule Regulators Targeting NAD+ Biosynthetic Enzymes.

Authors:  Alyson Curry; Dawanna White; Yana Cen
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

7.  NAMPT is the cellular target of STF-31-like small-molecule probes.

Authors:  Drew J Adams; Daisuke Ito; Matthew G Rees; Brinton Seashore-Ludlow; Xiaoling Puyang; Alex H Ramos; Jaime H Cheah; Paul A Clemons; Markus Warmuth; Ping Zhu; Alykhan F Shamji; Stuart L Schreiber
Journal:  ACS Chem Biol       Date:  2014-08-07       Impact factor: 5.100

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.